

IL17A

Research Grade Vunakizumab

Catalog No.	DHH28804A DHH28804B	Quantity:	100 µg 1.0 mg
Alternate Names:	Interleukin-17A, IL-17A, CTLA-8, SHR-1314		
Description:	Vunakizumab is an investigational, humanized monoclonal antibody targeting IL17A, with potential use in autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.		
Concentration:	1.0 mg/ml, lot specific		
UniProt ID (target):	Q16552		
Source:	XtenCHO cell line		
Isotype:	Human IgG1 kappa		
INN:	Vunakizumab		
Specificity:	Human IL-17A		
Endotoxin:	≤ 0.01 EU/µg by LAL analysis		
Formulation:	0.01M PBS, pH 7.4		
Purification:	Protein A/G affinity chromatography		
Purity:	> 95% as determined by SDS-PAGE		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com